Results of a phase I study in patients suffering from secondary-progressive multiple sclerosis demonstrating the safety of the amino acid copolymer PI-2301 and a possible induction of an anti-inflammatory cytokine response - Université de Rennes Access content directly
Journal Articles Journal of Neuroimmunology Year : 2010

Results of a phase I study in patients suffering from secondary-progressive multiple sclerosis demonstrating the safety of the amino acid copolymer PI-2301 and a possible induction of an anti-inflammatory cytokine response

J. Kovalchin
  • Function : Author
J. Krieger
  • Function : Author
M. Genova
  • Function : Author
K. Collins
M. Augustyniak
  • Function : Author
A. Masci
  • Function : Author
T. Hittinger
  • Function : Author
B. Kuca
  • Function : Author
U. Patel
  • Function : Author
E. Mascioli
  • Function : Author
E. Zanelli
  • Function : Author
  • PersonId : 1036428

Abstract

PI-2301 is an immunomodulator that could be an alternative therapy for MS. A placebo-controlled, multiple-ascending dose, double-blind study was performed in patients with secondary-progressive MS. Treatment was given subcutaneously once weekly for 8 weeks, followed by a 4-week open-label treatment period with active drug. The most common adverse event was transient injection site reactions. Non-significant trend for increases in serum levels of IL-3, IL-13, and CCL22 over time were suggestive of a beneficial T(H)2 immune response in subjects dosed with PI-2301 at 3 and 10 mg. MRI data indicated a non-significant trend for a reduction of lesion numbers in subjects treated with 1 and 3 mg PI-2301. (C) 2010 Elsevier B.V. All rights reserved.
Fichier principal
Vignette du fichier
Kovalchin et al_2010_Results of a phase I study in patients suffering from secondary-progressive.pdf (1.87 Mo) Télécharger le fichier
Origin : Files produced by the author(s)
Loading...

Dates and versions

hal-01874527 , version 1 (20-09-2018)

Identifiers

Cite

J. Kovalchin, J. Krieger, M. Genova, K. Collins, M. Augustyniak, et al.. Results of a phase I study in patients suffering from secondary-progressive multiple sclerosis demonstrating the safety of the amino acid copolymer PI-2301 and a possible induction of an anti-inflammatory cytokine response. Journal of Neuroimmunology, 2010, 225 (1-2), pp.153-163. ⟨10.1016/j.jneuroim.2010.04.008⟩. ⟨hal-01874527⟩
21 View
194 Download

Altmetric

Share

Gmail Facebook X LinkedIn More